Physician profile
Rita Maity
NPI 1649241472
$7,028.05
in general payments reported to CMS, 2019-2025
50 companies · $3,718 in 2025
The $3,718 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $118 · 2023: $682 · 2024: $2,510 · 2025: $3,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,798 · Honoraria: $560 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,798.13 |
| Honoraria | $560.00 |
| Education | $551.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $930.62 | 2024-2025 | |
| Daiichi Sankyo INC. | $798.81 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $491.72 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $475.38 | 2020-2025 | Jakafi, Jakafi, Monjuvi |
| Janssen Biotech, INC. | $403.51 | 2024-2025 | Rybrevant, Tecvayli, Talvey |
| Astellas Pharma US INC | $338.48 | 2024-2025 | Vyloy, Xospata, Xtandi |
| Glaxosmithkline, LLC. | $287.03 | 2024-2025 | Ojjaara, Blenrep |
| Astrazeneca Pharmaceuticals LP | $256.74 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $227.16 | 2024-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $223.13 | 2025 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $179.57 | 2025 | |
| Pfizer INC. | $175.77 | 2024-2025 | |
| Celgene Corporation | $172.81 | 2024-2025 | Reblozyl |
| Stemline Therapeutics INC. | $158.76 | 2023-2025 | Orserdu |
| Exelixis INC. | $143.85 | 2024-2025 | Cabometyx |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Maity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.